Emergent BioSolutions | EBS - Gross Profit On Sales

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $10M in Gross Profit on Sales for its fiscal quarter ending in March of 2023.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Coherus Biosciences USD 4.95M 15.34M Mar/2025
Exact Sciences USD 583.93M 21.48M Sep/2025
Exelixis USD 572.18M 7M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Lexicon Pharmaceuticals USD -16.16M 2.89M Jun/2024
Lonza CHF 1.29B 248M Jun/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Myriad Genetics USD 143.8M 8M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pacira USD 130.92M 5M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Xoma 992K 846K Jun/2024